Norgine, Axa and Debiopharm are in line for exits as the breast cancer diagnostics test provider is aiming to go public to boost research and development and commercial activities.
Agendia, a Netherlands-headquartered breast cancer diagnostics technology provider that counts insurance company Axa and pharmaceutical firms Debiopharm and Norgine as backers, filed for an initial public offering on the Nasdaq Global Market on Thursday.
Founded in 2003, Agendia developed two diagnostics systems, MammaPrint and Blueprint, designed respectively to assess the risk of a patient’s cancer recurring and to understand the underlying genetic reasons behind the growth of a tumour.
The company has filed to raise up to $75m and…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
